Please assess the completion status of the following clinical trial:

Trial Title: Evaluation of SARS-CoV-2 (COVID-19) Antibody-containing Plasma thErapy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Age \>1 year.~2. Active COVID-19 infection confirmed by positive SARS-CoV-2 PCR.~3. Meets institutional criteria for admission to hospital for COVID-19.~4. Admitted to ICU or non-ICU floor within 5 days of enrollment.~5. PaO2/FiO2 \>200 mmHg if intubated.~6. Patient or LAR able to provide informed consent.~Exclusion Criteria:~1. Previous treatment with convalescent plasma for COVID-19.~2. Current use of investigational antiviral therapy targeting SARS-CoV-2.~3. History of anaphylactic transfusion reaction.~4. Clinical diagnosis of acute decompensated heart failure.~5. Objection to blood transfusion.

- Gender: ALL
- Minimum Age: 12 Months
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Arm A (Type: EXPERIMENTAL): Two units of apheresis HT-CCP, collected from the same donor whenever possible, will be administered sequentially over no greater than a 24-hour period to participants randomized to Arm A. Each unit of HT-CCP will be approximately 250 mL, for a total transfused volume of approximately 500 mL.
- Arm B (Type: PLACEBO_COMPARATOR): Two units of FFP or FP24 (each 200-275 mL, approximately 500 mL total) will be administered sequentially to participants randomized to Arm B. (FFP/FP24 unit volumes vary more than apheresis plasma units. Two FFP/FP24 units that are approximately 250 mL apiece will be provided.)

Based on this trial design, predict the completion outcome and termination type (if applicable).